<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Drug Development Consultant &#38; Regulatory Consultant &#187; duodenal ulcer</title>
	<atom:link href="http://www.damienbove.com/tag/duodenal-ulcer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.damienbove.com</link>
	<description>Damien Bove Shares The Expertise</description>
	<lastBuildDate>Thu, 09 Feb 2012 16:32:39 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Drug Regulators Publish Draft Guidance on Helicobacter pylori associated Duodenal Ulcer Treatments</title>
		<link>http://www.damienbove.com/2009/11/05/drug-regulators-publish-draft-guidance-on-helicobacter-pylori-associated-duodenal-ulcer-treatments/</link>
		<comments>http://www.damienbove.com/2009/11/05/drug-regulators-publish-draft-guidance-on-helicobacter-pylori-associated-duodenal-ulcer-treatments/#comments</comments>
		<pubDate>Thu, 05 Nov 2009 20:12:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[clinical]]></category>
		<category><![CDATA[formulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[pre-clinical]]></category>
		<category><![CDATA[regulatory]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[duodenal ulcer]]></category>
		<category><![CDATA[helicobater pylori]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=903</guid>
		<description><![CDATA[The purpose of this guidance is to assist sponsors in clinical drug development for the treatment of adults with duodenal ulcers caused by Helicobacter pylori (H. pylori) for the reduction of duodenal ulcer recurrence. Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding the overall development program and clinical trial designs to support antimicrobial-containing H. pylori treatment regimens <a href="http://www.damienbove.com/2009/11/05/drug-regulators-publish-draft-guidance-on-helicobacter-pylori-associated-duodenal-ulcer-treatments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>Drug Regulators, FDA, CDER, Publish Draft Guidance on Helicobacter pylori associated Duodenal Ulcer Treatments</h1>
<p><a title="FDA CDER Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184500.pdf " target="_blank">full text here</a></p>
<p>The purpose of this guidance is to assist sponsors in clinical drug development for the treatment of adults with duodenal ulcers caused by Helicobacter pylori (H. pylori) for the reduction of duodenal ulcer recurrence. Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding the overall development program and clinical trial designs to support antimicrobial-containing H. pylori treatment regimens. This guidance intends to serve as a focus for continued discussions among the Division of Special Pathogen and Transplant Products, pharmaceutical sponsors, the academic community, and the public. As the science of this indication evolves, this guidance may be revised as new information accumulates.<br />
This guidance pertains to development of drugs for the treatment of adults with duodenal ulcers. It does not address treatment of children, or those with other conditions also associated with H. pylori, including gastric ulcers and non-ulcer dyspepsia. If sponsors are interested in pursuing an indication for the treatment of patients with other conditions associated with H. pylori infection or other endpoints not mentioned in this guidance, they are encouraged to discuss their proposals with the division. Sponsors desiring to pursue an indication for ulcers caused by clarithromycin-resistant organisms should discuss the types of data needed to support such a claim with the division early in drug development.</p>
<p class="MsoNormal">If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com</p>
<p>Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug  development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<p style="text-align: center;"><a title="How To Write a Business Plan" href="http://www.damienbove.com/how-to-write-a-business-plan/"><img class="size-full wp-image-640 aligncenter" title="How To Write A Business Plan" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/07/ida_100programme_515x64_LowRes.jpg" alt="ida 100programme 515x64 LowRes Drug Regulators Publish Draft Guidance on Helicobacter pylori associated Duodenal Ulcer Treatments" width="489" height="61" /></a></p>
<h1 style="text-align: left;">Turn your Business Into an Investor Magnet</h1>
<h2 style="text-align: left;">How to Write a Business Plan &#8211; Free E-Course</h2>
<p>Get the secrets that turns your project into an investment magnet, <strong>100% of our clients raise the finance they need to take their projects to the next stage</strong>, we will share these secrets with you. &#8211; <a title="How To Write a Business Plan" href="http://www.damienbove.com/how-to-write-a-business-plan/" target="_self">Sign up for Free</a></p>
<h1><strong>Grow your Expertise for Free</strong></h1>
<p><span style="font-weight: normal; font-size: 13px; ">As you know this website is a great resource for keeping up to date with developments and regulations, why not get our </span><span style="font-size: 13px; "><strong>FREE</strong></span><span style="font-weight: normal; font-size: 13px; "><strong> monthly regulatory and market round up</strong></span><span style="font-weight: normal; font-size: 13px; ">. You can un-subscribe at any time and we do not share your details with anybody.</span></p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" /></div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" /></div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Go »" /></div>
<input name="id" type="hidden" value="2" />
<input name="extra_ar" type="hidden" />
</form>
<div id="_mcePaste" style="overflow: hidden; position: absolute; left: -10000px; top: 0px; width: 1px; height: 1px;">This guideline ap</div>
<div id="_mcePaste" style="overflow: hidden; position: absolute; left: -10000px; top: 0px; width: 1px; height: 1px;">recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.</div>
<dl id="attachment_191" class="wp-caption aligncenter" style="display: block; margin-left: auto; margin-right: auto; text-align: center; background-color: #f3f3f3; padding-top: 4px; margin-top: 10px; margin-bottom: 10px; -webkit-border-top-right-radius: 3px 3px; -webkit-border-top-left-radius: 3px 3px; -webkit-border-bottom-left-radius: 3px 3px; -webkit-border-bottom-right-radius: 3px 3px; border: 1px solid #dddddd;">
<dt class="wp-caption-dt"><a href="http://www.damienbove.com/?page_id=183"><img class="size-full wp-image-191" style="padding: 0px; margin: 0px; border: 0px none initial;" title="Free Strategy Consultation - Biotech Pharma Regualtory" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/04/ida_consultants_freestrategyconsultation_515x64.jpg" alt="ida consultants freestrategyconsultation 515x64 Drug Regulators Publish Draft Guidance on Helicobacter pylori associated Duodenal Ulcer Treatments" width="515" height="64" /></a></dt>
</dl>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2009/11/05/drug-regulators-publish-draft-guidance-on-helicobacter-pylori-associated-duodenal-ulcer-treatments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

